ERBB2 and breast carcinoma: Concurrently, our understanding of breast cancer has evolved from a purely histopathologic classification toward intrinsic molecular subtypes such as luminal A, luminal B (HER2-negative and HER2-positive), HER2-enriched, and basal-like, each defined by distinct gene-expression profiles and carrying prognostic and predictive implications [6,8].